Orexin neurons receive glycinergic innervations.
Level 5 - mechanism / opinion, no new human data
Preclinical animal and in vitro mechanistic laboratory study
PubMed 21949857 · doi:10.1371/journal.pone.0025076
What was done
Mice received peripheral glycine injections during the dark period to assess sleep/wakefulness architecture and c-Fos activation in orexin neurons. Patch-clamp electrophysiology was performed on orexin neurons in the presence and absence of the glycine receptor antagonist strychnine. Triple-labeling immunofluorescence and double-labeling immunoelectron microscopy were used to evaluate glycinergic terminal apposition (GlyT2) and glycine receptor alpha-subunit localization on orexin neurons.
What was found
Peripheral glycine increased non-rapid eye movement (NREM) sleep time and reduced the total duration and mean episode duration of wakefulness, alongside inducing sleep/wakefulness fragmentation (no exact numerical values reported in abstract). Fos-positive orexin neurons markedly decreased following intraperitoneal glycine. Electrophysiologically, glycine directly induced hyperpolarization and stopped orexin neuron firing, an effect blocked by strychnine. Immunoelectron microscopy confirmed GlyT2-positive terminals forming symmetrical inhibitory synapses on orexin neuron somata and dendrites with postsynaptic glycine receptor alpha subunits.
Why it matters
This work identifies direct glycinergic synaptic inhibition of orexin neurons as a neurobiological mechanism through which glycine alters sleep-wake states and reduces wakefulness.
Limits
The study was conducted entirely in mice and rodent tissue slices. The abstract provides no sample sizes, effect sizes, or quantitative measurements for sleep parameters or electrophysiological recordings. Findings cannot be directly extrapolated to human dietary glycine supplementation without clinical confirmation.
Cited by
- supports Glycine promotes inhibitory neurotransmission to support sleep.